Molecular imaging to biomarker development in neuroscience

Area of Science:

• Neuroscience
• Pharmacology
• Medical Imaging

Background:

• Central nervous system (CNS) drug candidates exhibit >90% failure rates due to poor targeting, efficacy, or side effects.
• In vivo imaging presents a method to mitigate risks in drug development, though further research is needed.
• Development of biomarkers for disease mechanisms, efficacy, and toxicology is critical.

Purpose of the Study:

• To highlight the potential of in vivo imaging and biomarker development in CNS drug discovery.
• To emphasize the need for collaborative research across academia and industry.
• To discuss the evolution towards personalized medicine guided by molecular imaging.

Main Methods:

• Review of current trends in molecular biomarker imaging for CNS diseases.
• Analysis of the convergence of academic and pharmaceutical industry interests.
• Exploration of the role of imaging in guiding drug development and personalized therapy.

Main Results:

• Significant activity exists in target biomarker imaging, with ongoing research into mechanism, efficacy, and toxicology biomarkers.
• Biomarker tracers can be repurposed as diagnostic agents for guiding molecular therapy.
• Collaborative efforts are essential for advancing this field.

Conclusions:

• In vivo imaging and biomarker development are vital for improving CNS drug success rates.
• The integration of diagnostic imaging and therapeutic guidance supports personalized medicine.
• Cross-sector collaboration is key to realizing the full potential of molecular imaging in brain disease.